OCUPHIRE PHARMA INC (OCUP) Stock Price, Quote, News and Overview
NASDAQ:OCUP - Nasdaq - US67577R1023 - Common Stock - Currency: USD
OCUP Quote, Performance and Key Statistics
1.17
-0.16 (-12.03%)
The current stock price of OCUP is 1.17 USD. In the past month the price decreased by -9.3%. In the past year, price decreased by -57.61%.
OCUP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 68.04 | 838.54B | ||
| JNJ | JOHNSON & JOHNSON | 15.38 | 372.51B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 17.94 | 275.58B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.12 | 221.49B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.76 | 215.69B | ||
| MRK | MERCK & CO. INC. | 10.62 | 208.21B | ||
| PFE | PFIZER INC | 7.37 | 129.99B | ||
| SNY | SANOFI-ADR | 13.38 | 128.08B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.53 | 97.47B | ||
| GSK | GSK PLC-SPON ADR | 8.6 | 75.84B | ||
| ZTS | ZOETIS INC | 25.92 | 68.46B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.98 | 47.30B |
Related stock screener links
About OCUP
Company Profile
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 14 full-time employees. The company went IPO on 2004-11-30. The firm is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1α and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Company’s pipeline candidates include APX2009 and APX2014. The firm is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.
Company Info
OCUPHIRE PHARMA INC
37000 Grand River Ave., Suite 120
Farmington Hills MICHIGAN 48335 US
CEO: Mina Sooch
Employees: 14
Company Website: https://www.ocuphire.com/
Phone: 12486819815
OCUPHIRE PHARMA INC / OCUP FAQ
What is the stock price of OCUPHIRE PHARMA INC today?
The current stock price of OCUP is 1.17 USD. The price decreased by -12.03% in the last trading session.
What is the ticker symbol for OCUPHIRE PHARMA INC stock?
The exchange symbol of OCUPHIRE PHARMA INC is OCUP and it is listed on the Nasdaq exchange.
On which exchange is OCUP stock listed?
OCUP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for OCUPHIRE PHARMA INC stock?
9 analysts have analysed OCUP and the average price target is 17.09 USD. This implies a price increase of 1360.26% is expected in the next year compared to the current price of 1.17. Check the OCUPHIRE PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is OCUPHIRE PHARMA INC worth?
OCUPHIRE PHARMA INC (OCUP) has a market capitalization of 30.65M USD. This makes OCUP a Nano Cap stock.
How many employees does OCUPHIRE PHARMA INC have?
OCUPHIRE PHARMA INC (OCUP) currently has 14 employees.
What are the support and resistance levels for OCUPHIRE PHARMA INC (OCUP) stock?
OCUPHIRE PHARMA INC (OCUP) has a resistance level at 1.26. Check the full technical report for a detailed analysis of OCUP support and resistance levels.
Is OCUPHIRE PHARMA INC (OCUP) expected to grow?
The Revenue of OCUPHIRE PHARMA INC (OCUP) is expected to decline by -44.06% in the next year. Check the estimates tab for more information on the OCUP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy OCUPHIRE PHARMA INC (OCUP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OCUP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OCUP, evaluating the profitability, health, valuation and growth aspects
- OCUPHIRE PHARMA INC (OCUP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- OCUPHIRE PHARMA INC (OCUP) Sales and EPS estimates to see what analysts future expectations are.
- OCUPHIRE PHARMA INC (OCUP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- OCUPHIRE PHARMA INC (OCUP) Insider and Institutional Ownership to learn about the owners and their transactions.
- OCUPHIRE PHARMA INC (OCUP) Stock Chart to make your own analysis
- OCUPHIRE PHARMA INC (OCUP) Latest news and press-releases to stay up to date.
Does OCUPHIRE PHARMA INC (OCUP) stock pay dividends?
OCUP does not pay a dividend.
When does OCUPHIRE PHARMA INC (OCUP) report earnings?
OCUPHIRE PHARMA INC (OCUP) will report earnings on 2024-11-08, before the market open.
What is the Price/Earnings (PE) ratio of OCUPHIRE PHARMA INC (OCUP)?
OCUPHIRE PHARMA INC (OCUP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.55).
OCUP Technical Analysis
OCUP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to OCUP. OCUP has a great financial health rating, but its profitability evaluates not so good.
OCUP Financial Highlights
Over the last trailing twelve months OCUP reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS decreased by -165.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.46% | ||
| ROE | -34.71% | ||
| Debt/Equity | 0 |
OCUP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to OCUP. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -85.94% and a revenue growth -44.06% for OCUP